Related Experiment Video

Updated: Apr 24, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K

Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380

Shuhong Wu1, Li Wang1, Xiao Huang1

  • 1Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Bioorganic & Medicinal Chemistry
|September 4, 2014
PubMed

Insights

A novel prodrug, oncrasin-266, enhances the anticancer properties of NSC-743380 by improving stability and pharmacokinetics. This strategy reduces toxicity, offering a promising approach for KRAS-mutant cancers.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • NSC-743380 (oncrasin-72) is a novel anticancer agent with activity against KRAS-mutant cancers.
  • NSC-743380 exhibits poor stability due to dimer formation, limiting its therapeutic potential.
  • Improving the physicochemical properties of NSC-743380 is crucial for its clinical application.

Purpose of the Study:

  • To synthesize and evaluate oncrasin-266, a prodrug of NSC-743380, to enhance its anticancer efficacy and drug-like properties.
  • To assess the in vitro and in vivo stability, pharmacokinetics, tissue distribution, and safety profile of oncrasin-266 compared to NSC-743380.

Main Methods:

  • Synthetic lethality screening and lead compound optimization were used to develop NSC-743380.
  • Oncrasin-266 was synthesized by modifying NSC-743380 with cyclohexylacetic acid.
  • In vitro hydrolysis, stability studies, in vivo pharmacokinetic, tissue distribution, and toxicity assessments in mice were performed.

Main Results:

  • Oncrasin-266 demonstrated improved stability in powder, stock solutions, and spontaneous hydrolysis in vitro.
  • In vivo, oncrasin-266 effectively released NSC-743380, improving its pharmacokinetics and tissue distribution to tumors.
  • Oncrasin-266 exhibited better tolerability and reduced acute toxicity in mice compared to NSC-743380.

Conclusions:

  • The prodrug strategy significantly enhances the stability, pharmacokinetic profile, and safety of NSC-743380.
  • Oncrasin-266 represents a promising therapeutic agent for KRAS-mutant cancers by overcoming the limitations of the parent compound.
  • Prodrug development is an effective approach to optimize anticancer agents with suboptimal physicochemical properties.
Keywords:
CancerDrug developmentProdrugSynthetic lethality

More Related Videos

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.7K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

765

Related Concept Videos

Drug Product Stability01:16

Drug Product Stability

The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
369
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.1K
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
496
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
521